ibis mobile Releases Deep-Learning-Based Auto Paint for Drawing App ibis Paint
6.6.2017 12:00:00 EEST | Business Wire | Press release
ibis mobile inc. (head office: Chuo-ku, Tokyo; President/CEO: Eiji Kamiya) released an additional function for social drawing app ibis Paint. Using deep learning, the function enables automatic painting based on line drawings.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170606005695/en/
Deep-learning-based auto paint for drawing app ibis Paint (Graphic: Business Wire)
Watch how auto paint works
https://www.youtube.com/watch?v=YjCsASiOGmU
ibis Paint, a popular social drawing app with 8 million downloads, now features deep-learning-based automatic painting for line drawings. On the ibis Paint social site, many artworks are posted every day, with more than 600 thousand user-created works on the server. We selected about 300 thousand artworks suitable for deep learning from over 600 thousand posts, performed some image processing of the artworks in advance and used them to develop the new function through several months of trial and error-based research and development by using AWS’s machine learning cloud server (P2 instance) in Oregon in the U.S.
For users, this is a new art tool that is expected to enable new ways of expression. After the release, users’ posts on the ibis Paint social site are expected to help us understand their drawing trend, which will lead to higher accuracy and better recognition of diverse line drawings of people, objects, and landscapes.
The current function can recognize people’s face, hair, eye, cheek, and mouth, and lines between people and objects. Not all of these are painted with colors that users expect. An assist function addresses this situation, allowing users to specify colors. With this, users can paint in a short period of time.
This is our first commercial function that leverages deep learning. We plan to continue research to enable new ways of expression and labor saving using deep learning for drawing. Ultimately, we aim to develop artificial intelligence that assists professional cartoonists, illustrators, and animation creators to save labor and improve efficiency.
Fig. 1 shows how to experience AI auto paint. First, search ibis Paint
on App Store or Google Play Store, and download a free version. Then
have a line drawing ready.
1. Tap My Gallery on title screen
2.
Tap + on My Gallery
3. Tap Import Picture to load a line drawing
and adjust the loading position
4. Tap tool selection window
5.
Tap filters
6. Tap Auto Paint
Then auto paint is executed. If
you want to use the color specification assist function, open the color
selection window, choose a brush color, and apply color by tapping
inside the line drawing. The result is nicer when you put color with a
series of tapping motions rather than specifying a color with long lines.
Fig. 2 shows the results of some line drawings to which auto paint and color specification assist are applied.
|
App overview |
||
| Developer | ibis mobile inc. | |
| Name of app |
Free version: ibis Paint X |
|
| Category |
iOS: Entertainment |
|
| Supported OS |
Requires iOS 8.0 or later |
|
| Prices |
Free version: Free |
|
| ibisPaint.com |
Number of posts: 663,585 |
|
| Download app |
ibis Paint X iOS edition (free): |
|
| YouTube channel | ||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005695/en/
Contact information
Inquiries
ibis mobile inc.
Eiji Kamiya,
81(Japan)-3-6222-5277
President/CEO
mob-info@ibis.ne.jp
Website:
https://www.ibis.ne.jp/en_top/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
